Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azithromycin + methylprednisolone
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous, Oral, Intramuscular
01
Overview
A combination therapy consisting of azithromycin (a macrolide antibiotic) and methylprednisolone (a synthetic glucocorticoid). This combination is primarily used for treating refractory Mycoplasma pneumoniae pneumonia (RMPP), particularly in children. Azithromycin works by inhibiting bacterial protein synthesis, while methylprednisolone suppresses immune and inflammatory responses. Together, they effectively mitigate clinical symptoms, regulate inflammatory factors, and improve cellular immune dysfunction in RMPP patients. The combination has also been studied for use in COVID-19 treatment.
- Other names
- AzithromycinMethylprednisolone
02
Targets
23S rRNA (23S ribosomal RNA)GR (Glucocorticoid receptor)STAT3 (Signal Transducer and Activator of Transcription 3)
Beyond the preview
Go deeper on azithromycin + methylprednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azithromycin + methylprednisolone.